Ratings Protalix BioTherapeutics, Inc.

Equities

PLX

US74365A3095

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.15 ^USD	-2.54%		0.00%	-35.39%

Mar. 14	Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024
Mar. 14	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The group's activity appears highly profitable thanks to its outperforming net margins.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PROTALIX BIOTHERAPEUTICS, INC.	-35.39%	84.01M	-
IQVIA HOLDINGS INC.	+1.51%	42.75B	B
LONZA GROUP AG	+49.22%	41.61B	A
MODERNA, INC.	+8.57%	41.34B	B-
CELLTRION, INC.	-12.36%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B	B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+6.35%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes